Alnylam Pharmaceuticals Inc.

Alnylam is a leader in the emerging field of RNA interference-based therapeutics development, and the first to land a deal with a Big Pharma (Merck). Its focus is to discover and develop therapies for a range of diseases including viral infection, oncology, and autoimmune diseases.